PowerShares Intl Div Achiev ETF
Latest PowerShares Intl Div Achiev ETF News and Updates
Novo Nordisk Expects to Witness Strong Growth from New Product Launches
In addition to its robust drug portfolio, Novo Nordisk boasts a strong research pipeline in the diabetes, hemophilia, obesity, and growth disorder segments.
Novo Nordisk Is Expected to See Strong Growth in Insulin Segment
Insulin sales volumes sold across the world have grown at a compounded average growth rate (or CAGR) of 4.1% from May 2011 to May 2016.
Winning? We Review How Teva Dominates Generic Drug Space
Teva Pharmaceutical Industries plans to take advantage of market dynamics and unmet demand in generic pharmaceuticals by enacting a three-pronged strategy.
Will Sanofi See More Growth from Its Blockbuster Insulin Drug?
Sanofi’s diabetes franchise includes Lantus, Toujeo, Amaryl, and Apidra. Lantus, a glargine insulin, contributed 17% of total revenues in fiscal 2015.
GSK Optimistic about Future of Its Consumer Healthcare Segment
With improvements in the supply chain and successful launch of new products, GlaxoSmithKline (GSK) is optimistic about its consumer healthcare segment performance.
GlaxoSmithKline Giving a Shot to Its Vaccines Business
GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired Novartis’s (NVS) meningitis and other vaccines business.
GlaxoSmithKline’s Combo Treatment for HIV Faces Stiff Competition
GlaxoSmithKline’s (GSK) HIV medicines business is managed by ViiV Healthcare, a global specialist company in HIV medicines.
Analyzing Sanofi’s Asset Swap Deal with Boehringer Ingelheim
Sanofi is swapping its animal health business with Boehringer Ingelheim’s consumer healthcare business. The asset swap deal was signed on June 27, 2016.
Teva Pharmaceutical: A Successful Bond Financing Program in 2016
To finance the acquisition of Allergan Generics (AGN), Teva Pharmaceutical (TEVA) successfully completed a global bond offering on July 21, 2016.
What Happened to Sanofi’s Consumer Healthcare and Generics Franchise in 2Q16?
Sanofi’s Consumer Healthcare segment includes Allegra, Doliprane, Nasacort, and other products. It reported a 4.3% decline in revenues to 800 million euros.
Behind Sanofi’s Diabetes and Cardiovascular Performance in 2Q16
Sanofi’s Diabetes and Cardiovascular revenues declined by ~2% at constant exchange rates to 1.96 billion euros (about $2.21 billion) in 2Q16.
Genzyme Continued to Boost Growth for Sanofi in 2Q16
After Sanofi’s reorganization, Genzyme now includes products for multiple sclerosis, rare diseases, and oncology. Genzyme’s sales increased ~19.5% in 2Q16.
How Did Novo Nordisk Perform across Geographies in 1H16?
As of May 2016, Novo Nordisk (NVO) held a 46% share of the global total insulin market.
How Did GlaxoSmithKline’s Pharmaceuticals Segment Do in 2Q16?
GlaxoSmithKline’s (GSK) Pharmaceuticals segment declined substantially in 2015 due to the divestment of its oncology business to Novartis (NVS) in March 2015.
How Could the Novartis-Xencor Alliance Benefit Novartis?
As we’ve discussed, Novartis (NVS) is one of the largest pharmaceutical companies by revenue.
Novo’s Geographical Sales Split in 1Q16
Novo Nordisk’s US sales rose annually by 12% in local currency in 1Q16. North America remained its major market, constituting ~50% of its total revenue.
Shire’s Acquisition Gives It Natpara and Gattex
Gattex is the first and only analog of glucagon-like peptide-2 (or GLP-2) indicated for short bowel syndrome. The drug is known as Gattex in the United States and Revestive in Europe.
Novo Nordisk: Core Capabilities Differentiate It from Competition
Novo Nordisk has developed certain core capabilities that differentiate the company from its competition. One is establishing local organizations in emerging markets and then growing organically.